Provided by Tiger Trade Technology Pte. Ltd.

Urogen Pharma Ltd.

46.16
-0.7000-1.49%
Post-market: 46.160.00000.00%19:30 EDT
Volume:849.69K
Turnover:39.39M
Market Cap:2.25B
PE:-23.43
High:47.05
Open:46.52
Low:45.27
Close:46.86
52wk High:50.81
52wk Low:15.86
Shares:48.68M
Float Shares:43.35M
Volume Ratio:0.67
T/O Rate:1.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9700
EPS(LYR):-3.1901
ROE:-1481.26%
ROA:-18.06%
PB:-16.97
PE(LYR):-14.47

Loading ...

Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Urogen Pharma (URGN) and vTv Therapeutics (VTVT)

TIPRANKS
·
Jul 16

UroGen Pharma gets new US patent allowance into July 2044 for ZUSDURI, UGN-103

TIPRANKS
·
Jul 16

UroGen Pharma Receives US Patent Allowance for Zusduri, UGN-103

MT Newswires Live
·
Jul 15

Urogen Says USPTO Allows New Patent Claims for Zusduri, Ugn-103 Through July 2044

Reuters
·
Jul 15

Urogen Pharma CMO Mark Schoenberg Sells 10,000 Shares for $400,100

Reuters
·
Jul 11

Analysts Are Bullish on Top Healthcare Stocks: Urogen Pharma (URGN), Stoke Therapeutics (STOK)

TIPRANKS
·
Jul 09

UroGen Pharma Gets FDA Clearance to Begin Phase 1 Trial of UGN-501

MT Newswires Live
·
Jul 08

Urogen Says FDA Clears IND for Ugn-501 Oncolytic Virus in Bladder Cancer

Reuters
·
Jul 08

Urogen Pharma CMO Mark Schoenberg Disposes of $350,100 in Common Shares

Reuters
·
Jun 24

UroGen Pharma shareholders approve amended articles of association at annual meeting

Reuters
·
Jun 24

How Resolving Jelmyto Patent Litigation And Setting 2030 Generic Entry At UroGen Pharma (URGN) Has Changed Its Investment Story

Simply Wall St.
·
Jun 09

UroGen grants inducement RSUs for 102,700 shares to 21 new employees under 2019 plan

Reuters
·
Jun 05

Guggenheim Remains a Buy on Urogen Pharma (URGN)

TIPRANKS
·
Jun 04

UroGen Pharma Price Target Maintained With a $45.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 03

Update: UroGen Settles Patent Dispute With Teva; Generic Jelmyto Delayed Until 2030

MT Newswires Live
·
Jun 02

UroGen settles JELMYTO patent suit, grants Teva generic entry from Sept. 15, 2030

Reuters
·
Jun 02

Urogen Pharma (URGN) Receives a Buy from H.C. Wainwright

TIPRANKS
·
May 27

Sector Update: Health Care

MT Newswires Live
·
May 20

UroGen Pharma Investor Event Reinforced Zusduri Commercial Thesis, Oppenheimer Says

MT Newswires Live
·
May 19

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 19